Macquarie Group’s Cardlytics CDLX Stock Holding History

Macquarie Group’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-30	Closed	-$4K	–	1817
2022 Q3	$4K	Sell	30 -15	-33%	-$2.13K	﹤0.01%	2456
2022 Q2	$10K	Hold	45	–	–	﹤0.01%	2439
2022 Q1	$25	Hold	45	–	–	﹤0.01%	2329
2021 Q4	$30K	Hold	45	–	–	﹤0.01%	2297
2021 Q3	$38K	Hold	45	–	–	﹤0.01%	2306
2021 Q2	$57K	Sell	45 -3,256	-99%	-$3.67M	﹤0.01%	2132
2021 Q1	$3.62M	Buy	3,301 +245	+8%	+$324K	0.01%	998
2020 Q4	$4.36M	Buy	3,056 +2,971	+3,495%	+$3.17M	0.01%	911
2020 Q3	$60K	Hold	85	–	–	﹤0.01%	1912
2020 Q2	$59K	Buy	+85	New	+$49.1K	﹤0.01%	1889

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return

GEH

General Equity Holdings Brooklyn, New York $135M AUM 32.96% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

Macquarie Group's CDLX Position: Q4 2022 in Review

Macquarie Group sold out of Cardlytics (CDLX) in Q4 2022, closing a stake of 30 shares — an estimated $4K sold.

Macquarie Group first reported a position in CDLX in Q2 2020 and held it in 10 quarters. The position peaked at $4.36M in Q4 2020. 121 funds tracked by Wall St. Rank hold CDLX as of Q4 2022.

Macquarie Group reported no remaining Cardlytics position as of Q4 2022 after selling out during the quarter.
Macquarie Group sold 30 Cardlytics shares in Q4 2022, an estimated $4K.
Macquarie Group first reported a position in Cardlytics in Q2 2020 and held it in 10 quarters.
Macquarie Group's Cardlytics position peaked at $4.36M in Q4 2020.
121 funds tracked by Wall St. Rank held Cardlytics as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.